Free Trial
→ This is likely to EXPLODE (From Weiss Ratings) (Ad)tc pixel Free PYXS Stock Alerts

Pyxis Oncology (PYXS) Financials

Pyxis Oncology logo
$1.58 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$1.56 -0.02 (-0.95%)
As of 11/13/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Pyxis Oncology

Annual Income Statements for Pyxis Oncology

This table shows Pyxis Oncology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -13 -76 -121 -74 -77 -80
Consolidated Net Income / (Loss)		 -13 -76 -121 -74 -77 -80
Net Income / (Loss) Continuing Operations		 -13 -76 -121 -74 -77 -80
Total Pre-Tax Income 		-13 -76 -121 -74 -79 -78
Total Operating Income		 -13 -70 -123 -82 -89 -84
Total Gross Profit		 0.00 0.00 0.00 1.78 16 11
Total Revenue		 0.00 0.00 0.00 1.78 16 14
Operating Revenue		 - - 0.00 1.78 16 14
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.48 2.39
Operating Cost of Revenue		 - - - 0.00 0.48 2.39
Total Operating Expenses		 13 70 123 82 105 96
Selling, General & Admin Expense		 3.85 19 37 33 25 22
Research & Development Expense		 9.05 51 86 50 59 74
Impairment Charge		 - - - 0.00 21 0.00
Total Other Income / (Expense), net		 0.07 -6.03 2.76 8.41 9.97 6.19
Interest & Investment Income		 0.07 0.02 2.76 6.63 7.04 3.61
Other Income / (Expense), net		 0.00 -6.05 - - 2.93 2.58
Income Tax Expense		 - - - 0.00 -2.16 1.39
Basic Earnings per Share		 ($12.45) ($8.95) ($3.65) ($1.85) ($1.32) ($1.28)
Weighted Average Basic Shares Outstanding		 1.03M 8.49M 33.03M 39.90M 58.45M 62.14M
Diluted Earnings per Share		 ($12.45) ($8.95) ($3.65) ($1.85) ($1.32) ($1.28)
Weighted Average Diluted Shares Outstanding		 1.03M 8.49M 33.03M 39.90M 58.45M 62.14M
Weighted Average Basic & Diluted Shares Outstanding		 1.03M 8.49M 36.98M 58.13M 61.59M 62.83M

Quarterly Income Statements for Pyxis Oncology

This table shows Pyxis Oncology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -3.38 -17 -21 -36 -21 -18 -22 -18 -23 -25 -20
Consolidated Net Income / (Loss)		 -3.26 -17 -21 -36 -21 -18 -22 -18 -23 -25 -20
Net Income / (Loss) Continuing Operations		 -3.26 -17 -21 -36 -21 -18 -22 -18 -23 -25 -20
Total Pre-Tax Income 		-3.26 -17 -21 -38 -21 -18 -22 -17 -23 -25 -20
Total Operating Income		 -5.61 -20 -24 -40 -23 -20 -23 -18 -24 -26 -21
Total Gross Profit		 16 0.71 0.71 -2.21 0.52 2.82 0.68 6.77 0.63 0.39 0.00
Total Revenue		 17 0.71 0.71 -2.21 0.52 2.82 0.68 9.16 0.63 0.39 0.00
Operating Revenue		 17 0.71 0.71 -2.21 0.52 2.82 0.68 9.16 0.63 0.39 0.00
Total Cost of Revenue		 0.48 0.00 0.00 - 0.00 0.00 0.00 2.39 0.00 0.00 0.00
Total Operating Expenses		 21 20 24 40 23 23 23 27 24 26 21
Selling, General & Admin Expense		 8.25 6.08 6.01 5.08 5.87 5.44 5.65 5.23 4.38 9.93 3.97
Research & Development Expense		 13 14 18 14 17 17 18 22 20 16 17
Total Other Income / (Expense), net		 2.35 2.73 2.55 2.33 1.76 1.68 1.46 1.29 1.09 0.64 0.54
Interest & Investment Income		 1.55 2.02 1.85 1.62 1.24 1.00 0.77 0.60 0.46 0.26 0.54
Income Tax Expense		 - 0.00 0.00 - - 0.28 0.00 - - 0.00 0.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 0.12 0.04 -0.45 - 0.12 - -0.07 - 0.05 0.00 0.05
Basic Earnings per Share		 ($0.06) ($0.29) ($0.35) ($0.62) ($0.35) ($0.30) ($0.35) ($0.28) ($0.37) ($0.40) ($0.24)
Weighted Average Basic Shares Outstanding		 51.29M 60.50M 60.72M 58.45M 61.05M 61.92M 62.56M 62.14M 63.47M 63.99M 83.51M
Diluted Earnings per Share		 ($0.06) ($0.29) ($0.35) ($0.62) ($0.35) ($0.30) ($0.35) ($0.28) ($0.37) ($0.40) ($0.24)
Weighted Average Diluted Shares Outstanding		 51.29M 60.50M 60.72M 58.45M 61.05M 61.92M 62.56M 62.14M 63.47M 63.99M 83.51M
Weighted Average Basic & Diluted Shares Outstanding		 58.89M 58.94M 59.47M 61.59M 61.95M 62.02M 62.26M 62.83M 63.36M 83.41M 119.61M

Annual Cash Flow Statements for Pyxis Oncology

This table details how cash moves in and out of Pyxis Oncology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -12 268 -96 -170 9.81 -4.05
Net Cash From Operating Activities		 -10 -35 -89 -71 -58 -64
Net Cash From Continuing Operating Activities		 -10 -35 -89 -71 -58 -64
Net Income / (Loss) Continuing Operations		 -13 -76 -121 -74 -77 -80
Consolidated Net Income / (Loss)		 -13 -76 -121 -74 -77 -80
Depreciation Expense		 0.47 0.65 0.71 1.93 2.98 4.51
Amortization Expense		 - - 0.00 -4.79 -6.11 -2.96
Non-Cash Adjustments To Reconcile Net Income		 0.41 33 26 18 35 13
Changes in Operating Assets and Liabilities, net		 1.87 6.68 4.50 -12 -12 1.94
Net Cash From Investing Activities		 -1.48 -0.59 -6.40 -105 8.16 59
Net Cash From Continuing Investing Activities		 -1.48 -0.59 -6.40 -105 8.16 59
Purchase of Property, Plant & Equipment		 -1.48 -0.54 -6.40 -6.73 -0.24 -0.01
Acquisitions		 0.00 -0.05 0.00 0.00 0.00 0.00
Purchase of Investments		 - - 0.00 -197 -160 -107
Divestitures		 - - 0.00 6.66 0.00 0.00
Sale and/or Maturity of Investments		 - - 0.00 92 169 166
Net Cash From Financing Activities		 0.04 304 0.18 5.93 59 0.59
Net Cash From Continuing Financing Activities		 0.04 304 0.18 5.93 59 0.59
Issuance of Preferred Equity		 0.00 152 0.00 0.00 0.00 0.00
Issuance of Common Equity		 0.00 152 0.00 6.25 59 0.11
Other Financing Activities, net		 0.03 0.17 0.18 -0.33 0.06 0.48
Cash Interest Paid		 - - - 0.00 0.01 0.09
Cash Interest Received		 - 0.00 2.17 0.00 0.00 0.00
Cash Income Taxes Paid		 - 0.00 0.02 0.05 0.16 1.38

Quarterly Cash Flow Statements for Pyxis Oncology

This table details how cash moves in and out of Pyxis Oncology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents		 18 -2.89 -13 7.42 -6.71 -2.03 -1.81 6.50 -9.66 13 -15
Net Cash From Operating Activities		 -21 -3.01 -15 -19 -23 -17 -13 -10 -26 -18 -16
Net Cash From Continuing Operating Activities		 -21 -3.01 -15 -19 -23 -17 -13 -10 -26 -18 -16
Net Income / (Loss) Continuing Operations		 -3.26 -17 -21 -36 -21 -18 -22 -18 -23 -25 -20
Consolidated Net Income / (Loss)		 -3.26 -17 -21 -36 -21 -18 -22 -18 -23 -25 -20
Depreciation Expense		 1.12 0.59 0.73 0.55 0.55 0.54 0.53 2.90 0.46 0.30 0.30
Amortization Expense		 -1.29 -1.64 -1.65 -1.53 -1.16 -0.90 -0.53 -0.38 -0.24 -0.19 -0.34
Non-Cash Adjustments To Reconcile Net Income		 4.48 3.04 3.16 24 3.82 3.22 3.28 2.30 1.44 5.77 1.58
Changes in Operating Assets and Liabilities, net		 -22 12 4.30 -6.66 -4.60 -1.77 5.45 2.86 -4.39 1.27 2.15
Net Cash From Investing Activities		 -18 0.00 -0.01 27 16 15 11 16 16 21 -37
Net Cash From Continuing Investing Activities		 -18 0.00 -0.01 27 16 15 11 16 16 21 -37
Purchase of Investments		 -93 -39 -24 -4.37 -51 -41 -15 - -11 -3.00 -49
Sale and/or Maturity of Investments		 75 39 24 31 67 56 26 16 27 24 12
Net Cash From Financing Activities		 58 0.11 1.66 0.05 0.00 -0.07 -0.01 0.67 -0.03 9.99 39
Net Cash From Continuing Financing Activities		 58 0.11 1.66 0.05 0.00 -0.07 -0.01 0.67 -0.03 9.99 39
Issuance of Common Equity		 57 0.11 1.66 0.05 0.00 - - 0.11 0.00 10 38
Other Financing Activities, net		 0.05 0.01 -0.00 0.00 -0.00 -0.07 -0.01 0.56 -0.03 -0.01 0.24

Annual Balance Sheets for Pyxis Oncology

This table presents Pyxis Oncology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 10 280 211 174 157 92
Total Current Assets		 8.10 279 187 125 132 72
Cash & Equivalents		 8.08 275 179 9.66 19 15
Restricted Cash		 - 1.47 1.47 1.47 1.47 1.47
Short-Term Investments		 - - 0.00 110 107 51
Prepaid Expenses		 0.02 2.47 5.85 3.83 4.04 3.78
Plant, Property, & Equipment, net		 1.10 1.01 11 12 9.90 8.00
Total Noncurrent Assets		 0.95 0.34 14 37 15 11
Intangible Assets		 - - 0.00 24 2.60 0.00
Other Noncurrent Operating Assets		 0.95 0.34 14 13 12 11
Total Liabilities & Shareholders' Equity		 10 280 211 174 157 92
Total Liabilities		 3.85 19 51 48 36 38
Total Current Liabilities		 3.69 19 32 26 18 21
Accounts Payable		 1.08 12 7.10 3.90 4.86 11
Accrued Expenses		 2.00 6.59 25 13 11 8.55
Other Current Liabilities		 0.62 0.17 0.00 1.23 1.45 1.69
Total Noncurrent Liabilities		 0.17 0.00 19 22 19 17
Capital Lease Obligations		 - - - 0.00 0.10 0.02
Other Noncurrent Operating Liabilities		 0.17 0.00 19 20 19 17
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -16 261 161 126 121 53
Total Preferred & Common Equity		 -16 261 161 126 121 53
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -16 261 161 126 121 53
Common Stock		 0.10 353 373 412 484 497
Retained Earnings		 -16 -92 -212 -286 -364 -443
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 0.06 0.17 0.05

Quarterly Balance Sheets for Pyxis Oncology

This table presents Pyxis Oncology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets		 187 220 208 195 136 123 106 64 55 77
Total Current Assets		 139 172 161 149 112 100 83 46 37 59
Cash & Equivalents		 15 28 25 12 13 11 8.92 5.77 19 3.86
Restricted Cash		 1.47 1.47 1.47 1.47 1.47 1.47 1.47 1.47 1.47 1.47
Short-Term Investments		 118 129 131 133 93 78 67 35 14 52
Prepaid Expenses		 4.66 5.88 3.84 2.58 4.97 6.54 5.35 3.08 2.27 2.08
Plant, Property, & Equipment, net		 12 11 11 10 9.40 8.92 8.46 7.54 7.24 6.94
Total Noncurrent Assets		 35 37 36 36 15 14 14 11 11 11
Intangible Assets		 22 24 24 24 2.54 2.49 2.43 0.00 0.00 0.00
Other Noncurrent Operating Assets		 13 13 13 12 12 12 12 11 11 11
Total Liabilities & Shareholders' Equity		 187 220 208 195 136 123 106 64 55 77
Total Liabilities		 49 36 39 42 33 36 37 33 43 35
Total Current Liabilities		 28 14 17 20 14 18 19 17 27 20
Accounts Payable		 3.31 2.29 5.47 4.87 2.85 9.41 9.76 4.99 3.27 8.12
Accrued Expenses		 17 11 10 14 10 6.70 8.00 9.79 12 9.93
Other Current Liabilities		 1.20 1.02 1.34 1.39 1.51 1.57 1.63 1.76 12 1.89
Total Noncurrent Liabilities		 20 22 22 21 18 18 17 17 16 16
Capital Lease Obligations		 - - 0.14 0.12 0.08 0.06 0.04 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 20 20 19 19 18 18 17 16 16 16
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 138 184 170 154 103 88 69 31 11 41
Total Preferred & Common Equity		 138 184 170 154 103 88 69 31 11 41
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 138 184 170 154 103 88 69 31 11 41
Common Stock		 409 474 477 481 488 491 494 498 503 553
Retained Earnings		 -271 -289 -307 -328 -385 -403 -425 -466 -492 -512
Accumulated Other Comprehensive Income / (Loss)		 -0.11 -0.06 -0.10 0.35 0.05 -0.01 0.07 0.00 -0.00 -0.06

Annual Metrics And Ratios for Pyxis Oncology

This table displays calculated financial ratios and metrics derived from Pyxis Oncology's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 32,763,887.00 35,097,256.00 44,323,046.00 59,465,729.00 62,264,215.00
DEI Adjusted Shares Outstanding		 0.00 32,763,887.00 35,097,256.00 44,323,046.00 59,465,729.00 62,264,215.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -2.32 -3.44 -1.66 -1.30 -1.28
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 809.12% -14.17%
EBITDA Growth		 0.00% -504.59% -64.38% 31.12% -5.41% 10.45%
EBIT Growth		 0.00% -487.61% -62.97% 33.43% -5.28% 5.42%
NOPAT Growth		 0.00% -440.69% -77.12% 33.43% -8.84% 5.63%
Net Income Growth		 0.00% -492.26% -58.89% 38.87% -4.80% -2.96%
EPS Growth		 0.00% 28.11% 59.22% 49.32% 28.65% 3.03%
Operating Cash Flow Growth		 0.00% -250.32% 0.00% 20.85% 18.44% -10.11%
Free Cash Flow Firm Growth		 0.00% 0.00% -128.04% -1.26% 39.16% -3.22%
Invested Capital Growth		 0.00% -735.33% -33.89% 124.74% -253.06% -97.27%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -14.72% 155.82%
EBITDA Q/Q Growth		 0.00% 0.00% -21.95% 0.00% -27.99% 25.76%
EBIT Q/Q Growth		 0.00% 0.00% -21.14% 0.00% -28.85% 22.93%
NOPAT Q/Q Growth		 0.00% 0.00% -21.14% 0.00% -33.21% 20.50%
Net Income Q/Q Growth		 0.00% 0.00% -19.00% 0.00% -34.82% 17.99%
EPS Q/Q Growth		 0.00% 0.00% -112.09% 0.00% -26.92% 20.99%
Operating Cash Flow Q/Q Growth		 0.00% -34.20% 0.00% 2.93% -7.52% 12.25%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 10.66%
Invested Capital Q/Q Growth		 0.00% 0.00% -77.05% 0.00% -200.60% -67.28%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 100.00% 97.06% 82.77%
EBITDA Margin		 0.00% 0.00% 0.00% -4,789.25% -555.31% -579.41%
Operating Margin		 0.00% 0.00% 0.00% -4,628.15% -554.07% -609.18%
EBIT Margin		 0.00% 0.00% 0.00% -4,628.15% -535.95% -590.60%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -4,154.84% -478.95% -574.55%
Tax Burden Percent		 100.00% 100.31% 100.00% 100.00% 97.28% 101.77%
Interest Burden Percent		 99.49% 99.97% 97.76% 89.77% 91.87% 95.59%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -203.72% -56.78% -57.19% -51.51% -62.75% -91.43%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -1,670.29% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -42.69% -52.30% -65.82%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -38.32% -46.74% -64.03%
Return on Common Equity (ROCE)		 506.14% -52.12% -57.19% -51.51% -62.75% -91.43%
Return on Equity Simple (ROE_SIMPLE)		 81.99% -29.07% -75.06% -58.70% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -9.03 -49 -86 -58 -63 -59
NOPAT Margin		 0.00% 0.00% 0.00% -3,239.71% -387.85% -426.43%
Net Nonoperating Expense Percent (NNEP)		 -47.06% -19.12% -15.00% -10.78% -11.81% -20.88%
Return On Investment Capital (ROIC_SIMPLE)		 - - -53.75% -45.77% -51.82% -110.60%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 2.94% 17.23%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 1,836.15% 157.44% 160.15%
R&D to Revenue		 0.00% 0.00% 0.00% 2,792.00% 363.85% 531.79%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 4,628.15% 651.13% 691.95%
Earnings before Interest and Taxes (EBIT)		 -13 -76 -123 -82 -87 -82
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -12 -75 -123 -85 -90 -80
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.36 0.28 0.57 0.76 1.34
Price to Tangible Book Value (P/TBV)		 0.00 0.36 0.28 0.71 0.77 1.34
Price to Revenue (P/Rev)		 0.00 0.00 0.00 40.44 5.65 5.16
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.23
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.28 -1.06 -1.08 -1.05 -1.01 -1.13
Leverage Ratio		 1.61 1.08 1.16 1.34 1.34 1.43
Compound Leverage Factor		 1.60 1.08 1.14 1.21 1.23 1.37
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.08% 0.04%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.08% 0.04%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 348.45% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -248.45% 100.00% 100.00% 100.00% 99.92% 99.96%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 1.43 0.85
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 2.05 1.16
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 20.31 2.75 -1.93 -2.28 -2.57 -7.79
Noncontrolling Interest Sharing Ratio		 348.45% 8.20% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 2.20 14.90 5.90 4.84 7.49 3.41
Quick Ratio		 2.19 14.69 5.67 4.63 7.18 3.16
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -36 -81 -82 -50 -52
Operating Cash Flow to CapEx		 -679.97% -6,541.85% 0.00% -1,051.28% -24,334.18% -705,577.78%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.01 0.10 0.11
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.15 1.48 1.55
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.11 0.30
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 3,363.76 1,203.22
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 -3,363.76 -1,203.22
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -1.78 -15 -20 4.93 -7.55 -15
Invested Capital Turnover		 0.00 0.00 0.00 -0.24 -12.33 -1.23
Increase / (Decrease) in Invested Capital		 0.00 -13 -5.05 25 -12 -7.35
Enterprise Value (EV)		 182 -183 -137 -49 -37 3.16
Market Capitalization		 168 93 44 72 91 71
Book Value per Share		 ($15.18) $7.98 $4.58 $2.84 $2.03 $0.86
Tangible Book Value per Share		 ($15.18) $7.98 $4.58 $2.29 $1.99 $0.86
Total Capital		 6.30 261 161 126 121 53
Total Debt		 0.00 0.00 0.00 0.00 0.10 0.02
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.10 0.02
Net Debt		 -8.08 -276 -181 -121 -128 -68
Capital Expenditures (CapEx)		 1.48 0.54 0.00 6.73 0.24 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.67 -16 -26 -22 -14 -17
Debt-free Net Working Capital (DFNWC)		 4.41 260 155 99 115 51
Net Working Capital (NWC)		 4.41 260 155 99 115 51
Net Nonoperating Expense (NNE)		 3.80 27 34 16 15 21
Net Nonoperating Obligations (NNO)		 -8.08 -276 -181 -121 -128 -68
Total Depreciation and Amortization (D&A)		 0.47 0.65 0.00 -2.86 -3.13 1.55
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -1,234.52% -84.50% -125.23%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 5,565.60% 710.76% 367.83%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 5,565.60% 710.76% 367.83%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($8.95) ($3.65) ($1.85) ($1.32) ($1.28)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 32.84M 33.03M 39.90M 58.45M 62.14M
Adjusted Diluted Earnings per Share		 $0.00 ($8.95) ($3.65) ($1.85) ($1.32) ($1.28)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 32.84M 33.03M 39.90M 58.45M 62.14M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($8.95) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 8.49M 36.98M 58.13M 61.59M 62.83M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.03 -49 -86 -58 -48 -59
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -3,239.71% -296.96% -426.43%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -4,154.84% -492.35% -564.55%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Pyxis Oncology

This table displays calculated financial ratios and metrics derived from Pyxis Oncology's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding		 58,133,375.00 58,888,473.00 58,942,243.00 59,465,729.00 61,590,415.00 61,947,665.00 62,018,135.00 62,264,215.00 62,831,246.00 63,355,482.00 83,408,050.00
DEI Adjusted Shares Outstanding		 58,133,375.00 58,888,473.00 58,942,243.00 59,465,729.00 61,590,415.00 61,947,665.00 62,018,135.00 62,264,215.00 62,831,246.00 63,355,482.00 83,408,050.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.06 -0.29 -0.35 -0.60 -0.35 -0.30 -0.35 -0.29 -0.37 -0.40 -0.24
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 44,492.11% 25.53% 17.89% -484.03% -96.96% 394.92% -2.98% 513.88% 22.52% -86.21% -100.00%
EBITDA Growth		 72.97% -11.80% 2.68% -121.69% -307.11% 4.61% 4.90% 61.58% -2.64% -33.23% 12.38%
EBIT Growth		 73.25% -10.55% 6.31% -125.52% -308.81% 1.41% 1.23% 54.34% -6.31% -36.32% 12.52%
NOPAT Growth		 73.25% -10.55% 6.31% -125.52% -308.81% 1.41% 1.23% 54.34% -6.31% -31.59% 12.52%
Net Income Growth		 83.08% -8.80% 8.01% -128.06% -549.82% -6.09% -3.77% 49.10% -9.99% -38.10% 9.18%
EPS Growth		 88.89% 29.27% 37.50% -82.35% -483.33% -3.45% 0.00% 54.84% -5.71% -33.33% 31.43%
Operating Cash Flow Growth		 22.84% 72.74% 0.00% -26.46% -8.81% -474.09% 9.46% 45.95% -15.38% -5.46% -22.72%
Free Cash Flow Firm Growth		 9.07% -4.74% 16.81% 58.29% 147.23% 106.05% 99.96% 64.91% -171.63% 31.19% -77,715.46%
Invested Capital Growth		 1,811.85% 0.00% 0.00% -253.06% -114.50% -121.29% -218.64% -97.27% -201.51% -749.43% -76.56%
Revenue Q/Q Growth		 2,841.84% -95.82% -0.42% -413.76% 123.28% 580.39% -80.48% 1,238.45% -93.11% -38.35% -100.00%
EBITDA Q/Q Growth		 68.80% -264.95% -17.04% -66.37% 42.71% 14.49% -16.68% 32.78% -53.05% -7.22% 20.56%
EBIT Q/Q Growth		 68.45% -257.40% -18.58% -68.68% 42.81% 13.81% -18.79% 22.02% -33.15% -6.69% 21.04%
NOPAT Q/Q Growth		 68.45% -257.40% -18.58% -68.68% 42.81% 13.81% -18.79% 22.02% -33.15% -6.69% 21.04%
Net Income Q/Q Growth		 79.12% -431.36% -22.55% -67.76% 40.52% 13.25% -19.88% 17.71% -28.53% -8.91% 21.16%
EPS Q/Q Growth		 82.35% -383.33% -20.69% -77.14% 43.55% 14.29% -16.67% 20.00% -32.14% -8.11% 40.00%
Operating Cash Flow Q/Q Growth		 -35.77% 85.48% -387.70% -31.54% -16.82% 23.39% 23.09% 21.47% -149.35% 29.98% 10.50%
Free Cash Flow Firm Q/Q Growth		 24.32% 5.25% 9.79% 35.52% 185.71% -87.86% -100.60% -56,193.81% -74.97% 122.23% -455.37%
Invested Capital Q/Q Growth		 420.00% -50.37% -41.04% -200.60% 50.73% 27.14% -228.51% -67.28% 24.69% -105.26% 31.72%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 97.20% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 73.92% 100.00% 100.00% 0.00%
EBITDA Margin		 -34.09% -2,977.82% -3,500.00% 0.00% -4,566.80% -573.94% -3,430.70% -172.29% -3,825.67% -6,653.73% 0.00%
Operating Margin		 -33.08% -2,829.38% -3,369.36% 0.00% -4,449.32% -563.64% -3,429.97% -199.84% -3,860.54% -6,681.23% 0.00%
EBIT Margin		 -33.08% -2,829.38% -3,369.36% 0.00% -4,449.32% -563.64% -3,429.97% -199.84% -3,860.54% -6,681.23% 0.00%
Profit (Net Income) Margin		 -19.22% -2,443.64% -3,007.52% 0.00% -4,108.35% -523.80% -3,216.81% -197.77% -3,688.11% -6,515.68% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 94.27% 100.00% 101.57% 100.00% 106.49% 100.00% 100.00% 100.00%
Interest Burden Percent		 58.09% 86.37% 89.26% 94.18% 92.34% 91.50% 93.79% 92.94% 95.53% 97.52% 97.37%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -32.05% -5,856.92% -11,897.39% 0.00% 0.00% -428.17% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -32.48% -5,852.75% -11,891.13% 0.00% 0.00% -424.51% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 29.87% 2,917.58% 5,960.24% 0.00% 0.00% 407.98% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -2.18% -2,939.34% -5,937.14% -62.75% -66.30% -20.19% -87.28% -91.43% -121.66% -179.10% -157.51%
Cash Return on Invested Capital (CROIC)		 -526.74% -956.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -3.07% -277.72% -334.01% 0.00% 0.00% -18.49% -123.49% -22.27% -539.02% -865.87% 0.00%
Return on Assets (ROA)		 -1.78% -239.86% -298.14% 0.00% 0.00% -17.18% -115.82% -22.04% -514.95% -844.41% 0.00%
Return on Common Equity (ROCE)		 -2.18% -2,939.34% -5,937.14% -62.75% -66.30% -20.19% -87.28% -91.43% -121.66% -179.10% -157.51%
Return on Equity Simple (ROE_SIMPLE)		 -31.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.92 -14 -17 -28 -16 -14 -16 -13 -17 -18 -14
NOPAT Margin		 -23.15% -1,980.57% -2,358.55% 0.00% -3,114.52% -394.55% -2,400.98% -139.89% -2,702.38% -4,676.86% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.43% -4.17% -6.26% -6.04% -3.86% -3.66% -4.99% -5.39% -8.33% -11.46% -8.34%
Return On Investment Capital (ROIC_SIMPLE)		 -2.13% -8.25% -10.81% -23.21% -15.55% -15.76% -23.86% -23.97% -54.53% -159.03% -34.77%
Cost of Revenue to Revenue		 2.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 26.08% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 48.67% 858.62% 852.91% 0.00% 1,139.81% 155.17% 826.46% 57.17% 693.66% 2,553.47% 0.00%
R&D to Revenue		 76.89% 1,970.76% 2,516.45% 0.00% 3,309.51% 488.96% 2,603.51% 237.15% 3,166.88% 4,127.76% 0.00%
Operating Expenses to Revenue		 125.56% 2,829.38% 3,369.36% 0.00% 4,449.32% 644.12% 3,429.97% 294.32% 3,860.54% 6,681.23% 0.00%
Earnings before Interest and Taxes (EBIT)		 -5.61 -20 -24 -40 -23 -20 -23 -18 -24 -26 -21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.78 -21 -25 -41 -24 -20 -23 -16 -24 -26 -21
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.19 1.18 1.45 0.76 0.58 0.78 2.02 1.34 2.96 16.84 4.71
Price to Tangible Book Value (P/TBV)		 1.36 1.37 1.71 0.77 0.59 0.80 2.09 1.34 2.96 16.84 4.71
Price to Revenue (P/Rev)		 11.69 10.64 11.77 5.65 0.00 12.53 25.64 5.16 6.63 16.69 17.92
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.34 3.39 10.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 3.21 2.29 4.05 0.00 0.00 0.00 11.30 0.23 3.59 13.70 12.67
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.92 -0.50 -0.50 -1.01 -0.92 -0.96 -1.01 -1.13 -1.11 -1.26 -1.22
Leverage Ratio		 1.20 1.22 1.31 1.34 1.24 1.29 1.35 1.43 1.49 1.80 1.66
Compound Leverage Factor		 0.70 1.05 1.17 1.26 1.14 1.18 1.27 1.33 1.42 1.75 1.61
Debt to Total Capital		 0.00% 0.08% 0.08% 0.08% 0.08% 0.07% 0.06% 0.04% 0.01% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.08% 0.08% 0.08% 0.08% 0.07% 0.06% 0.04% 0.01% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 99.92% 99.92% 99.92% 99.92% 99.93% 99.94% 99.96% 99.99% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 2.19 2.09 1.43 0.97 0.83 0.72 0.85 0.51 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 3.26 3.11 2.05 1.43 1.21 1.05 1.16 0.71 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 2.66 1.66 1.35 -1.60 -2.57 -3.11 -3.33 -5.49 -8.96 -11.03 -6.17
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 12.19 9.53 7.33 7.49 7.75 5.65 4.29 3.41 2.76 1.34 2.96
Quick Ratio		 11.67 9.22 7.13 7.18 7.31 5.20 3.93 3.16 2.48 1.20 2.79
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -28 -27 -24 -16 13 1.62 -0.01 -5.46 -9.55 2.12 -7.55
Operating Cash Flow to CapEx		 -8,738.40% 0.00% 0.00% 0.00% 0.00% 0.00% -147,522.22% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.09 0.10 0.10 0.10 0.00 0.03 0.04 0.11 0.14 0.13 0.12
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.53 1.59 1.68 1.48 0.00 0.54 0.57 1.55 1.65 1.43 1.41
Accounts Payable Turnover		 0.15 0.14 0.12 0.11 0.00 0.00 0.00 0.30 0.61 0.38 0.27
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 2,427.44 2,603.03 3,142.84 3,363.76 0.00 0.00 0.00 1,203.22 598.78 969.13 1,366.46
Cash Conversion Cycle (CCC)		 -2,427.44 -2,603.03 -3,142.84 -3,363.76 0.00 0.00 0.00 -1,203.22 -598.78 -969.13 -1,366.46
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 26 13 7.51 -7.55 -3.72 -2.71 -8.91 -15 -11 -23 -16
Invested Capital Turnover		 1.38 2.96 5.04 -12.33 0.00 1.09 -7.74 -1.23 -1.87 -0.90 -0.88
Increase / (Decrease) in Invested Capital		 24 13 7.51 -12 -29 -15 -16 -7.35 -7.50 -20 -6.82
Enterprise Value (EV)		 60 43 77 -37 -47 -22 61 3.16 50 158 138
Market Capitalization		 218 200 223 91 60 68 139 71 93 193 195
Book Value per Share		 $3.17 $2.88 $2.61 $2.03 $1.67 $1.41 $1.11 $0.86 $0.50 $0.18 $0.50
Tangible Book Value per Share		 $2.76 $2.48 $2.21 $1.99 $1.63 $1.37 $1.07 $0.86 $0.50 $0.18 $0.50
Total Capital		 184 170 154 121 103 88 69 53 31 11 41
Total Debt		 0.00 0.14 0.12 0.10 0.08 0.06 0.04 0.02 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.14 0.12 0.10 0.08 0.06 0.04 0.02 0.00 0.00 0.00
Net Debt		 -158 -157 -146 -128 -107 -90 -78 -68 -42 -34 -57
Capital Expenditures (CapEx)		 0.24 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.26 -13 -18 -14 -9.46 -8.14 -14 -17 -13 -25 -18
Debt-free Net Working Capital (DFNWC)		 158 144 129 115 97 82 64 51 29 9.26 39
Net Working Capital (NWC)		 158 144 129 115 97 82 64 51 29 9.26 39
Net Nonoperating Expense (NNE)		 -0.67 3.28 4.58 7.52 5.12 4.53 5.58 5.30 6.22 7.15 5.62
Net Nonoperating Obligations (NNO)		 -158 -157 -146 -128 -107 -90 -78 -68 -42 -34 -57
Total Depreciation and Amortization (D&A)		 -0.17 -1.05 -0.92 -0.98 -0.61 -0.36 -0.01 2.52 0.22 0.11 -0.04
Debt-free, Cash-free Net Working Capital to Revenue		 -1.40% -69.34% -93.70% -84.50% 0.00% -149.65% -259.13% -125.23% -96.25% -218.38% -164.46%
Debt-free Net Working Capital to Revenue		 846.96% 765.61% 678.93% 710.76% 0.00% 1,513.02% 1,175.76% 367.83% 207.81% 80.22% 360.85%
Net Working Capital to Revenue		 846.96% 765.61% 678.93% 710.76% 0.00% 1,513.02% 1,175.76% 367.83% 207.81% 80.22% 360.85%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.06) ($0.29) ($0.35) ($0.62) ($0.35) ($0.30) ($0.35) ($0.28) ($0.37) ($0.40) ($0.24)
Adjusted Weighted Average Basic Shares Outstanding		 51.29M 60.50M 60.72M 58.45M 61.05M 61.92M 62.56M 62.14M 63.47M 63.99M 83.51M
Adjusted Diluted Earnings per Share		 ($0.06) ($0.29) ($0.35) ($0.62) ($0.35) ($0.30) ($0.35) ($0.28) ($0.37) ($0.40) ($0.24)
Adjusted Weighted Average Diluted Shares Outstanding		 51.29M 60.50M 60.72M 58.45M 61.05M 61.92M 62.56M 62.14M 63.47M 63.99M 83.51M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 58.89M 58.94M 59.47M 61.59M 61.95M 62.02M 62.26M 62.83M 63.36M 83.41M 119.61M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.92 -14 -17 -28 -16 -14 -16 -13 -17 -18 -14
Normalized NOPAT Margin		 -23.15% -1,980.57% -2,358.55% 0.00% -3,114.52% -394.55% -2,400.98% -139.89% -2,702.38% -4,676.86% 0.00%
Pre Tax Income Margin		 -19.22% -2,443.64% -3,007.52% 0.00% -4,108.35% -515.72% -3,216.81% -185.72% -3,688.11% -6,515.68% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Pyxis Oncology’s latest statements show a cash-funded clinical-stage biotech with persistent operating losses, declining liquidity and continued reliance on external financing. The company generated only $389,000 of revenue in Q2 2026, down from $631,000 in Q1 2026 and $2.82 million in the restated year-ago quarter. Revenue has been highly volatile, including $9.16 million in Q4 2025 and $16.95 million in Q1 2024, rather than showing a consistent growth trend.

  • Q2 2026 investing activity increased cash by $21.3 million. The company received $24.3 million from investment maturities or sales, partially offset by $3.0 million of investment purchases.
  • Pyxis raised $10.0 million through common-equity issuance in Q2 2026. This helped offset its operating cash burn and contributed to a $13.1 million increase in cash and equivalents during the quarter.
  • There is no meaningful capital lease burden. Capital lease obligations declined from $3,000 in Q1 2026 to zero in Q2, limiting one source of balance-sheet pressure.
  • Interest and investment income remains a modest offset to operating losses. Q2 2026 interest and investment income was $255,000, while total other income was $644,000; however, these amounts are not large enough to materially change the company’s loss profile.
  • Operating losses continue to widen. Q2 2026 operating expenses were $26.0 million, producing an operating loss of $26.0 million despite $389,000 of revenue. Net loss attributable to common shareholders was $25.35 million, or $0.40 per share, compared with a $23.33 million loss, or $0.37 per share, in Q1.
  • Research and development spending remains substantial relative to revenue. Q2 R&D expense was $16.1 million, or more than 40 times quarterly revenue. Selling, general and administrative expense added another $9.9 million.
  • Cash flow remains heavily negative. Net cash used in operating activities was $18.2 million in Q2 2026 and $26.0 million in Q1. Combined operating cash usage for the first half of 2026 was approximately $44.2 million.
  • Liquidity has deteriorated sharply over the longer term. Cash, restricted cash and short-term investments totaled approximately $35.1 million at June 30, 2026, down from $43.5 million at March 31 and $93.7 million at June 30, 2025. Total assets fell to $54.9 million from $123.2 million a year earlier.
  • The balance sheet has limited equity support relative to ongoing losses. Total liabilities were $43.5 million against only $11.4 million of shareholders’ equity at June 30, 2026. Retained earnings were negative $491.8 million, reflecting the company’s accumulated losses.
  • Additional capital raises may create dilution risk. Weighted-average basic shares outstanding increased to 64.0 million in Q2 2026 from 62.0 million in the restated Q2 2025. With continuing operating cash burn and a relatively small liquid-asset base, Pyxis may need further equity or other financing if its pipeline does not begin generating significant cash.

Overall, the statements indicate that Pyxis Oncology remains dependent on its cash reserves, investment maturities and capital markets rather than internally generated cash flow. The Q2 equity raise and investment proceeds improved near-term cash, but the company’s declining liquidity, recurring losses and uncertain revenue base remain significant risks for investors.

11/14/26 02:38 AM ETAI Generated. May Contain Errors.

Pyxis Oncology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Pyxis Oncology's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Pyxis Oncology's net income appears to be on a downward trend, with a most recent value of -$79.62 million in 2025, falling from -$12.83 million in 2020. The previous period was -$77.33 million in 2024. View Pyxis Oncology's forecast to see where analysts expect Pyxis Oncology to go next.

Pyxis Oncology's total operating income in 2025 was -$84.42 million, based on the following breakdown:
  • Total Gross Profit: $11.47 million
  • Total Operating Expenses: $95.89 million

Over the last 5 years, Pyxis Oncology's total revenue changed from $0.00 in 2020 to $13.86 million in 2025, a change of 1,385,800,000.0%.

In the past 12 quarters, Pyxis Oncology's cash and equivalents has ranged from $3.86 million in Q3 2026 to $27.97 million in Q1 2024, and is currently $3.86 million as of their latest financial filing in Q3 2026.

Pyxis Oncology had total debt of $23 thousand at the end of 2025, a 77.0% decrease from 2024, and none in 2020.

Over the last 5 years, Pyxis Oncology's book value per share changed from -15.18 in 2020 to 0.86 in 2025.


Related Companies

Financial statements for NASDAQ:PYXS last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...
Behind the Markets | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...
Paradigm Press | Sponsoredtc pixel
Management just bought 2.8 million shares
Management just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...
Monument Traders Alliance | Sponsoredtc pixel
Executive Order 14241 Unleashes Trump’s New Dollar
A landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...
Porter & Company | Sponsoredtc pixel
My next big call (under $1)
17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...
Crypto 101 Media | Sponsoredtc pixel